Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing
Lausanne, Switzerland (ots/PRNewswire) – Diagnoplex, a developer of molecular cancer diagnostics today announced the closing of a Series A financing raising CHF10 million ($8.3 million). The A-round...
View ArticleRoche to Present Major Advances With Targeted Cancer Medicines at ASCO
Basel, Switzerland (ots/PRNewswire) – – EMBARGOED: Not for publication until: 14 May at 23:00 BST More than 500 scientific abstracts to be presented across 20 types of cancers. Results could...
View ArticleAgendia to Present Multiple Predictive and Prognostic Studies on Breast and...
Huntington Beach, California and Amsterdam (ots/PRNewswire) – Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of...
View ArticleRoche to Present New Survival Data From Phase II, III and IV Studies for...
Basel, Switzerland (ots/PRNewswire) – – Nearly 150 Abstracts Covering New Tumour Types, New Patient Groups and Existing Indications to Feature in ECCO-ESMO Program Roche will present encouraging...
View ArticleAgendia Presents Broad Array of Predictive and Prognostic Studies on Breast...
Huntington Beach, California and Amsterdam, June 4, 2010 (ots/PRNewswire) — Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic...
View ArticleAgendia Publishes Compelling First Independent Validation Study of Colon...
Irvine, California and Amsterdam (ots/PRNewswire) – Agendia, a world leader in molecular cancer diagnostics, announced today that together with principal investigators from Spain, the UK, and the...
View ArticleAgendia Announces Intention to List on NYSE Euronext in Amsterdam
Amsterdam (ots/PRNewswire) – Agendia (the “Company”), a commercial-stage molecular diagnostic company with operations in the Netherlands and the United States, announces today its intention to raise...
View ArticleAgendia Announces Six Studies in Breast and Colon Cancer for Presentation at...
Amsteram and Irvine, California (ots/PRNewswire) – Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it will present results from four completed and one ongoing...
View ArticleBrennpunkt Darmkrebs: Europas Patienten rufen zu verstärktem Handeln auf /...
London (ots) – Darmkrebspatienten aus ganz Europa werden noch lange von der Patientenkonferenz “Colorectal Cancer Patient Conference”, die am Wochenende in Barcelona stattfand, profitieren: Mit knapp...
View ArticleColorectal Cancer Patients Call for European Action / The Power of Patient...
London (ots) – Colorectal cancer (CRC) patients from across Europe benefited greatly from the Colorectal Cancer Patient Conference that took place in Barcelona last weekend: With almost 200 attendees...
View ArticleAgendia Receives ?1.27 Million in Funding from the EU’s Seventh Framework...
Irvine, California and Amsterdam (ots/PRNewswire) – – Company Will Develop Companion Diagnostics With Consortiums of Leading European Cancer Centers and Translational Research Groups Agendia, a global...
View ArticleEANS-News: Epigenomics Septin9 Biomarker detects Colon Cancer equally in both...
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– New Products/Company...
View Article
